See more : Wesure Global Tech Ltd (WESR.TA) Income Statement Analysis – Financial Results
Complete financial analysis of PolyPid Ltd. (PYPD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PolyPid Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Guangzhou Jinyi Media Corporation (002905.SZ) Income Statement Analysis – Financial Results
- Baotou Huazi Industry Co., Ltd (600191.SS) Income Statement Analysis – Financial Results
- Maxicity Holdings Limited (8216.HK) Income Statement Analysis – Financial Results
- Panacea Life Sciences Holdings, Inc. (PLSH) Income Statement Analysis – Financial Results
- Clever Global, S.A. (CLE.MC) Income Statement Analysis – Financial Results
PolyPid Ltd. (PYPD)
About PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.82M | 1.72M | 1.12M | 1.01M | 947.00K | 411.00K | 205.00K | 127.00K | 108.00K | 0.00 | 0.00 |
| Gross Profit | -1.82M | -1.72M | -1.12M | -1.01M | -947.00K | -411.00K | -205.00K | -127.00K | -108.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.15M | 27.99M | 30.42M | 16.95M | 14.08M | 12.55M | 9.74M | 7.71M | 5.63M | 2.64M | 1.38M |
| General & Administrative | 0.00 | 8.01M | 9.48M | 7.70M | 4.48M | 5.27M | 4.06M | 2.55M | 2.93M | 938.00K | 410.00K |
| Selling & Marketing | 0.00 | 2.89M | 2.97M | 1.61M | 887.00K | 549.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.90M | 10.90M | 12.45M | 9.32M | 4.48M | 5.81M | 4.06M | 2.55M | 2.93M | 938.00K | 410.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.05M | 38.89M | 42.88M | 26.27M | 18.56M | 18.36M | 13.80M | 10.26M | 8.57M | 3.58M | 1.79M |
| Cost & Expenses | 22.87M | 38.89M | 42.88M | 26.27M | 18.56M | 18.36M | 13.80M | 10.26M | 8.57M | 3.58M | 1.79M |
| Interest Income | 548.00K | 267.00K | 468.00K | 474.00K | 60.00K | 126.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.71M | 1.02M | 0.00 | 17.00K | 15.00K | 42.00K | 40.69M | 1.13M | -1.53M | 0.00 | 0.00 |
| Depreciation & Amortization | 1.82M | 1.72M | 1.12M | 1.01M | 947.00K | 411.00K | 205.00K | 127.00K | 108.00K | 71.00K | 60.00K |
| EBITDA | -20.26M | -36.37M | -41.48M | -35.86M | -5.94M | -42.15M | -13.60M | -10.13M | -7.95M | -3.51M | -1.73M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.87M | -38.89M | -42.88M | -26.27M | -18.56M | -18.36M | -13.80M | -10.26M | -11.28M | -3.58M | -1.79M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -929.00K | -540.00K | 544.00K | -10.60M | 11.66M | 24.28M | -40.69M | -1.13M | -1.18M | -305.00K | -3.00K |
| Income Before Tax | -23.80M | -39.43M | -42.33M | -36.87M | -6.91M | 5.92M | -54.49M | -11.39M | -9.75M | -3.88M | -1.79M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 69.00K | 97.00K | -1.62M | -1.55M | -11.66M | -24.28M | 40.69M | 1.13M | -1.53M | 305.00K | 3.00K |
| Net Income | -23.87M | -39.53M | -40.71M | -35.32M | 4.75M | 5.92M | -54.49M | -11.39M | -8.22M | -3.88M | -1.79M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.99 | -61.04 | -65.24 | -110.59 | 10.72 | 13.35 | -185.29 | -38.74 | -18.81 | -19.79 | -4.04 |
| EPS Diluted | -16.99 | -61.04 | -65.24 | -110.59 | 10.72 | 13.35 | -185.29 | -38.74 | -18.81 | -19.79 | -4.04 |
| Weighted Avg Shares Out | 1.40M | 647.56K | 624.05K | 319.41K | 443.22K | 443.22K | 294.07K | 294.07K | 437.07K | 196.22K | 443.22K |
| Weighted Avg Shares Out (Dil) | 1.40M | 647.56K | 624.05K | 319.41K | 443.22K | 443.22K | 294.07K | 294.07K | 437.07K | 196.22K | 443.22K |
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company's management will present at the Cantor Global Healthcare Conference taking place on...
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health
Successful Audit of the Company's State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ Globally Successful Audit of the Company's State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ Globally
PolyPid Announces Reverse Share Split
PETACH TIKVA, Israel, Sept. 20, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announces a reverse share split (the “Reverse Split”) of the Company's issued and outstanding ordinary...
PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀
Company has Successfully Completed the Production of Three Process Validation Batches at Commercial Scale Completes a Substantial Requirement Toward the Planned Submission of D-PLEX 100 NDA and MAA Regulatory Filings PETACH TIKVA, Israel, Sept. 19, 2023 (GLOBE NEWSWIRE) -- PolyPid...
PolyPid Ltd (PYPD) Q2 2023 Earnings Call Transcript
PolyPid Ltd (NASDAQ:PYPD ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Dikla Akselbrad - CEO & Director Jonny Missulawin - CFO Ori Warshavsky - COO Conference Call Participants Douglas...
PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial E valuating D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections
PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023
PETACH TIKVA, Israel, July 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2023 financial results and operational highlights...
PolyPid to Participate in Upcoming Investor Conferences
PETACH TIKVA, Israel, April 24, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that members of management will participate in the following upcoming investor conferences:
PolyPid Ltd (PYPD) Q4 2022 Earnings Call Transcript
PolyPid Ltd (NASDAQ:PYPD ) Q4 2022 Earnings Conference Call February 8, 2023 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Dikla Akselbrad - CEO Ori Warshavsky - COO, US Jonny Missulawin - SVP, Finance Conference Call Participants Brandon...
PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023
PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full year 2022 financial results and...
Source: https://incomestatements.info
Category: Stock Reports